RxDoctor Payments Data

Luciano Iorizzo, MD

MOHS-Micrographic Surgery · York, PANPI 1386813012

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 32.7% of the total. Reporting peaked in 2019 at $279 and has fallen 78.9% since, to $59 in 2025. That places this record below the midpoint for mohs-micrographic surgery clinicians in PA, where the typical reported total is $1,161.

$534in general payments, 2019–2025

Across 31 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$175
  • Genentech USA, Inc.$73
  • Johnson & Johnson$46
  • Regeneron Healthcare Solutions, Inc.$42
  • Pfizer$32
  • Sun Pharmaceutical Industries Inc.$30
  • plus $136 from 7 others

What the payments were for

  • Food & beverage$51897%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$534 in reported general payments places this provider in the 25th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.

See all mohs-micrographic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$722,389
Medicare patients
601
Services billed
2,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil33$2,725
Clobetasol Propionate11$209
Doxycycline Hyclate15$78
Cephalexin18$40

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →